ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI
https://abvcpharma.com/wp-content/themes/movedo/images/empty/thumbnail.jpg
150
150
Press Release
https://secure.gravatar.com/avatar/ccdf917cf35d7f34fb2fe57df9e6cb93?s=96&d=mm&r=g
FREMONT, CA – July 9, 2024 – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that after successful Phase II clinical trials of their medication…
read more